Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease. Chetwood JD, Arzivian A, Tran Y, Paramsothy S, et al. Aliment Pharmacol Ther 2025 Jul 10. doi: 10.1111/apt.70267.

Read + Share

Amedeo Smart

Independent Medical Education

Chetwood JD, Arzivian A, Tran Y, Paramsothy S, et al. Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease. Aliment Pharmacol Ther 2025 Jul 10. doi: 10.1111/apt.70267.
PMID: 40641122